Generic medicines: Perceptions of consumers in Melbourne, Australia

International Journal of Pharmacy Practice

Volumn 13, Issue 4, 2005, Pages 257-264

  Hassali, Mohamed Azmi ^a   Kong, David C M ^a,b   Stewart, Kay ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; AUSTRALIA; CONSUMER; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE DELIVERY; HUMAN; INTERVIEW; PATIENT EDUCATION; PERCEPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

EID: 28544431994     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/ijpp.13.4.0004     Document Type: Article

References (48)

1. Kanavos P. Financing pharmaceuticals in transition economies. Croat Med J 1999;40:244-59.
2. Karim S, Pillai G, Ziqubu-Page TT, Cassimjee MH, Morar MS. Potential savings from generic prescribing and generic substitution in South Africa. Health Policy Plan 1996;11: 198-205.
3. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J 2002;43:462-9.
4. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials: Volume 1. Geneva: World Health Organization; 1997.
5. Carroll NV. Impact of generic and therapeutic interchange incentives on community pharmacy. Am Pharm 1995;NS35:27-34.
6. Mrazek MF, Mossialos E. Increasing demand while decreasing costs of generic medicines. Lancet 2000;356:1784-5.
7. Naidoo R. Generic medicines: defining the boundaries. Pharm Cosmet Rev 2002;29:34-5.
8. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiol Drug Saf 2001;10:295-300.
9. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff(Millwood) 2001;20:104-14.
10. Smeaton J. The generics market. Aust J Pharm 2000;81:540-2.
11. Lofgren H. Generics drugs: international trends and policy developments in Australia. Aust Health Rev 2004; 27:39-48.
12. Pharmaceutical Benefits Pricing Authority. Annual report for the year ended 30 June 2003. Canberra: Australian Government Printing Service; 2003. p 12.
13. McGavock H. Generic substitution: issues relating to the Australian experience. Pharmacoepidemiol Drug Saf 2001; 10:555-6.
14. Burton B. Changing prescription software to favour generics could save Australia 40 million pounds a year. BMJ 2003;326:184.
15. Department of Health and Ageing. About the PBS. www.health.gov.au/ internet/wcms/publishing.nsf/Content/ health-pbs-general-aboutus.htm-copy2 (accessed August 5, 2005)
16. Scuderi M. Generic substitution in a Brisbane community pharmacy. Aust Pharm 2002;21:116-21.
17. Podulka M, Krautkramer K, Amerson D. Consumers' attitudes toward generic drugs. J Pharm Mark Manage 1989;4: 93-104.
18. Sansgiry S, Bhosle M. Consumer perceptions of generic drug substitution practices in the USA. J Pharm Pract Res 2004;34:262-6.
19. Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumer's views on generic medications. J Am Pharm Assoc 2001;41:729-36.
20. Berg B. Qualitative research methods for the social sciences, 5th ed. Boston: Allyn and Bacon; 2004. p 15
21. Smith F. Qualitative interviews. Research methods in pharmacy practice. London: Pharmaceutical Press; 2002. pp 119-22.
22. Quine S. Interviews. In: Kerr C, Taylor R, Heard G, editors. Handbook of public health methods. Sydney: McGraw-Hills; 1998. pp 522-6.
23. Berg B. Qualitative research methods for the social sciences, 5th ed. Boston: Allyn and Bacon; 2004. pp 36-7.
24. Kirking DM, Ascione FJ. Perspectives on generic pharmaceuticals: some conclusions. J Am Pharm Assoc 2001;41: 826-8.
25. Kendall KW, Ng S, Schoner B. Consumer response to generic/chemically equivalent drugs. J Pub Pol Mark 1991;10: 182-201.
26. Lockney A. Generic Medicines. inPHARMation (Pharmaceutical Society of Australia) 2003;4:6-10.
27. Rosendahl I. Consumers on generics:some clues on their views from AARP. Drug Topics 1994;suppl(May):54S-56S.
28. Carroll NV, Wolfgang A, Kotzan J, Perri M. Consumer attitudes and actions toward generic drugs. J Pharm Mark Manage 1988;2:87-99.
29. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000;40:378-83.
30. Sanderson J, Lewis J. Differences in side-effect incidence in patients on proprietary and generic propranolol. Lancet 1986;26:967-8.
31. Locniskar A, Greenblatt D, Harmatz J, Shader R. Bioinequivalence of generic brand of diazepam. Biopharm Drug Dispos 1989;10:597-605.
32. Lesser RP, Krauss G. Buy some today: can generics be safely substituted for brand-name drugs? Neurology 2001; 57:571-3.
33. Donovan J. Is there a role for generic medicines in the pharmaceutical benefits scheme? Health Issues (Melbourne, Australia) 2003;75(Winter):9-11.
34. Pharmaceutical Benefits Pricing Authority. Annual report for the year ended 30 June 2003. Canberra: Australian Government Printing Service; 2003. p 12.
35. Fogg S. Informing consumer. Aust Prescr 2003;26:2-3.
36. Webber GC. Patient education: a review of the issues. Med Care 1990;28:1089-103.
37. Livingstone CR, Pugh AL, Winn S, Williamson VK. Developing community pharmacy services wanted by local people: information and advice about prescription medicines. Int J Pharm Pract 1996;4:94-102.
38. Messenger A. Substitution bitter pill to swallow for some. Austr Doctor 1995;(16 June):4.
39. Stevens A, Fogg S, Healy-North J, Hobbs M, Bell K, Tatchell M. A question of generics. Aust J Pharm 1993;74: 469-71.
40. Brand P, Clear P, Keen S et al. Brand substitution. Aust Pharm 1995;14:646-9.
41. McAdam NW. Patients' attitudes to generic prescribing. J R Coll Gen Pract 1986;36:288.
42. Yelland MJ, Veitch PC. How do patients identify their drugs? Aust Fam Phys 1989;18:1441-5.
43. Sorensen L, Stokes JA, Woodward M, Roberts MS. Medication misadventure risks-findings at home visits. In: Hodgson WC, Loicano RE, editors. Proceedings of the Annual Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, Newcastle, Australia. Dec 3-6, 2000. p 100.
44. Birkett DJ. Generics equal or not? Aust Prescr 2003;26:85-7.
45. Probyn A. Some drugs more equal than others: pseudogenerics and commercial practice. Aust Health Rev 2004; 28:207-17.
46. Hassali A, Stewart K, Kong D. Quality use of generic medicines. Aust Prescr 2004;27:80-1.
47. Guadagnoli E, Ward P. Patient participation in decision-making. Soc Sci Med 1998;47:329-39.
48. Coulter A. After Bristol: putting patients at the centre. Qual Saf Health Care 2002;11:186-8.